CD8A and neoplasm: Although additional experiments will be needed to fully understand the factors contributing to the systemic activation that we observed, regardless of the exact mechanism, our data indicate that targeting tumor-cell intrinsic STING signaling through intratumoral combination therapy is capable of priming antitumor CD8+ T cell responses.